A Phase 1b/2 Study to Evaluate the Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer
Latest Information Update: 28 Sep 2023
At a glance
- Drugs Sabizabulin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Veru Healthcare
- 22 Sep 2023 Status changed to discontinued due to administrative decision.
- 16 Jun 2023 Status changed from active, no longer recruiting to completed.
- 22 Mar 2023 Planned primary completion date changed from 28 Feb 2023 to 31 Mar 2023.